ABVC BioPharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release (Form 10-Q) | 14 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly140.3KTarget: Sufficient to cover operating cash burn and eliminate going concern risk
Working Capital Deficit Quarterly-4.7MTarget: Positive working capital
Quarterly Net Loss Quarterly-1.7MTarget: Breakeven or net profitability through licensing milestones
Watch Items
- Going Concern StatusTrigger: Continued lack of revenue and cash reserves below quarterly operating burnAction: Secure additional equity financing, debt restructuring, or accelerate licensing milestone payments from affiliates
- ABV-1504 (MDD) FDA Phase III InitiationTrigger: Successful End of Phase II (EOP II) meeting with the FDA and securing a Phase III co-development partnerAction: Finalize clinical trial protocols and execute out-licensing agreements with major pharmaceutical partners
- Licensing Collections from AffiliatesTrigger: Delays in receiving scheduled payments from AiBtl BioPharma, OncoX BioPharma, or ForSeeCon Eye CorporationAction: Enforce contractual payment terms or convert outstanding licensing receivables into equity/tangible assets
Research as of 19 Jun 2026